Consistent with this hypothesis, CD39 was recently identified as a marker to distinguish tumor antigen-specific CD8+ T cells from bystander T cells across multiple tumor types (32, 107) and stratification of patients based on frequency of CD39+CD103+ double positive CD8+ T cells associated with increased overall survival in head and neck cancer patients (107). The gene discussed is CD8A; the disease is head and neck cancer.